HC Wainwright Analysts Give Cytosorbents (CTSO) a $15.00 Price Target

HC Wainwright set a $15.00 price objective on Cytosorbents (NASDAQ:CTSO) in a report issued on Wednesday. The brokerage currently has a buy rating on the medical research company’s stock.

Several other analysts also recently weighed in on CTSO. BidaskClub downgraded shares of Cytosorbents from a hold rating to a sell rating in a research note on Tuesday, October 9th. Cowen restated a buy rating and issued a $15.00 price objective on shares of Cytosorbents in a research report on Friday, August 3rd. Finally, Maxim Group restated a buy rating and issued a $18.00 price objective on shares of Cytosorbents in a research report on Tuesday, September 4th. One research analyst has rated the stock with a sell rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of Buy and an average target price of $14.81.

Cytosorbents stock traded down $0.86 during mid-day trading on Wednesday, hitting $9.85. The company’s stock had a trading volume of 182,279 shares, compared to its average volume of 233,952. The company has a quick ratio of 8.60, a current ratio of 7.03 and a debt-to-equity ratio of 0.49. The company has a market capitalization of $358.93 million, a PE ratio of -30.78 and a beta of 0.62. Cytosorbents has a 12 month low of $5.80 and a 12 month high of $14.95.

Cytosorbents (NASDAQ:CTSO) last posted its quarterly earnings results on Wednesday, November 7th. The medical research company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.04. The business had revenue of $5.74 million during the quarter, compared to the consensus estimate of $5.79 million. Cytosorbents had a negative net margin of 70.97% and a negative return on equity of 90.18%. As a group, equities analysts expect that Cytosorbents will post -0.55 earnings per share for the current fiscal year.

In other Cytosorbents news, insider Phillip P. Chan sold 11,418 shares of the business’s stock in a transaction dated Friday, September 7th. The shares were sold at an average price of $14.65, for a total value of $167,273.70. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, COO Vincent Capponi sold 9,565 shares of the business’s stock in a transaction dated Tuesday, August 28th. The shares were sold at an average price of $13.00, for a total transaction of $124,345.00. Following the transaction, the chief operating officer now owns 342,333 shares in the company, valued at approximately $4,450,329. The disclosure for this sale can be found here. Insiders sold 65,501 shares of company stock worth $927,310 in the last 90 days. Corporate insiders own 6.90% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. increased its position in shares of Cytosorbents by 14.9% during the third quarter. BlackRock Inc. now owns 1,961,749 shares of the medical research company’s stock valued at $25,308,000 after buying an additional 254,902 shares during the period. PNC Financial Services Group Inc. increased its position in shares of Cytosorbents by 48.8% during the third quarter. PNC Financial Services Group Inc. now owns 30,500 shares of the medical research company’s stock valued at $393,000 after buying an additional 10,000 shares during the period. Bank of New York Mellon Corp increased its position in shares of Cytosorbents by 14.0% during the third quarter. Bank of New York Mellon Corp now owns 94,814 shares of the medical research company’s stock valued at $1,224,000 after buying an additional 11,666 shares during the period. Pitcairn Co. purchased a new position in shares of Cytosorbents during the third quarter valued at about $147,000. Finally, Mycio Wealth Partners LLC purchased a new position in shares of Cytosorbents during the third quarter valued at about $166,000. Institutional investors own 24.79% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors.

See Also: Put Option

Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply